ID   GLI3_HUMAN              Reviewed;        1580 AA.
AC   P10071; A4D1W1; O75219; Q17RW4; Q75MT0; Q75MU9; Q9UDT5; Q9UJ39;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 6.
DT   07-APR-2021, entry version 218.
DE   RecName: Full=Transcriptional activator GLI3;
DE   AltName: Full=GLI3 form of 190 kDa;
DE            Short=GLI3-190;
DE   AltName: Full=GLI3 full-length protein;
DE            Short=GLI3FL;
DE   Contains:
DE     RecName: Full=Transcriptional repressor GLI3R;
DE     AltName: Full=GLI3 C-terminally truncated form;
DE     AltName: Full=GLI3 form of 83 kDa;
DE              Short=GLI3-83;
GN   Name=GLI3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ALA-183 AND LEU-998.
RX   PubMed=2118997; DOI=10.1128/mcb.10.10.5408;
RA   Ruppert J.M., Vogelstein B., Arheden K., Kinzler K.W.;
RT   "GLI3 encodes a 190-kilodalton protein with multiple regions of GLI
RT   similarity.";
RL   Mol. Cell. Biol. 10:5408-5415(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS GCPS GLY-515 AND TYR-520, AND
RP   VARIANTS ALA-183; GLU-440; MET-808; LEU-998 AND CYS-1537.
RX   PubMed=10441342; DOI=10.1093/hmg/8.9.1769;
RA   Kalff-Suske M., Wild A., Topp J., Wessling M., Jacobsen E.-M.,
RA   Bornholdt D., Engel H., Heuer H., Aalfs C.M., Ausems M.G.E.M., Barone R.,
RA   Herzog A., Heutink P., Homfray T., Gillessen-Kaesbach G., Koenig R.,
RA   Kunze J., Meinecke P., Mueller D., Rizzo R., Strenge S., Superti-Furga A.,
RA   Grzeschik K.-H.;
RT   "Point mutations throughout the GLI3 gene cause Greig
RT   cephalopolysyndactylysyndrome.";
RL   Hum. Mol. Genet. 8:1769-1777(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ALA-183 AND LEU-998.
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 500-549.
RX   PubMed=2850480; DOI=10.1128/mcb.8.8.3104;
RA   Ruppert J.M., Kinzler K.W., Wong A.J., Bigner S.H., Kao F.T., Law M.L.,
RA   Seuanez H.N., O'Brien S.J., Vogelstein B.;
RT   "The GLI-Kruppel family of human genes.";
RL   Mol. Cell. Biol. 8:3104-3113(1988).
RN   [7]
RP   FUNCTION, PROTEOLYTIC PROCESSING, PHOSPHORYLATION AT SER-849; SER-865;
RP   SER-877; SER-907; SER-980 AND SER-1006, AND MUTAGENESIS OF SER-849;
RP   SER-865; SER-877; SER-907; SER-980 AND SER-1006.
RX   PubMed=10693759; DOI=10.1016/s0092-8674(00)80678-9;
RA   Wang B., Fallon J.F., Beachy P.A.;
RT   "Hedgehog-regulated processing of Gli3 produces an anterior/posterior
RT   repressor gradient in the developing vertebrate limb.";
RL   Cell 100:423-434(2000).
RN   [8]
RP   FUNCTION, INTERACTION WITH ZIC1, AND SUBCELLULAR LOCATION.
RX   PubMed=11238441; DOI=10.1074/jbc.c000773200;
RA   Koyabu Y., Nakata K., Mizugishi K., Aruga J., Mikoshiba K.;
RT   "Physical and functional interactions between Zic and Gli proteins.";
RL   J. Biol. Chem. 276:6889-6892(2001).
RN   [9]
RP   PROTEOLYTIC PROCESSING, PHOSPHORYLATION, INTERACTION WITH BTRC,
RP   UBIQUITINATION AT LYS-773; LYS-779; LYS-784 AND LYS-800, AND MUTAGENESIS OF
RP   LYS-773; LYS-779; LYS-784; LYS-800; SER-849; SER-855; SER-856; SER-861;
RP   SER-864; SER-873; SER-877; SER-903 AND SER-907.
RX   PubMed=16705181; DOI=10.1128/mcb.02183-05;
RA   Tempe D., Casas M., Karaz S., Blanchet-Tournier M.F., Concordet J.P.;
RT   "Multisite protein kinase A and glycogen synthase kinase 3beta
RT   phosphorylation leads to Gli3 ubiquitination by SCFbetaTrCP.";
RL   Mol. Cell. Biol. 26:4316-4326(2006).
RN   [10]
RP   PROTEOLYTIC PROCESSING, PHOSPHORYLATION, POLYUBIQUITINATION, AND
RP   INTERACTION WITH BTRC.
RX   PubMed=16371461; DOI=10.1073/pnas.0509927103;
RA   Wang B., Li Y.;
RT   "Evidence for the direct involvement of {beta}TrCP in Gli3 protein
RT   processing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:33-38(2006).
RN   [11]
RP   PHOSPHORYLATION.
RX   PubMed=18455992; DOI=10.1016/j.cell.2008.02.047;
RA   Varjosalo M., Bjorklund M., Cheng F., Syvanen H., Kivioja T., Kilpinen S.,
RA   Sun Z., Kallioniemi O., Stunnenberg H.G., He W.W., Ojala P., Taipale J.;
RT   "Application of active and kinase-deficient kinome collection for
RT   identification of kinases regulating hedgehog signaling.";
RL   Cell 133:537-548(2008).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH ZIC3.
RX   PubMed=17764085; DOI=10.1002/humu.20606;
RA   Zhu L., Zhou G., Poole S., Belmont J.W.;
RT   "Characterization of the interactions of human ZIC3 mutants with GLI3.";
RL   Hum. Mutat. 29:99-105(2008).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH KIF7.
RX   PubMed=19592253; DOI=10.1016/j.cub.2009.06.046;
RA   Endoh-Yamagami S., Evangelista M., Wilson D., Wen X., Theunissen J.W.,
RA   Phamluong K., Davis M., Scales S.J., Solloway M.J., de Sauvage F.J.,
RA   Peterson A.S.;
RT   "The mammalian Cos2 homolog Kif7 plays an essential role in modulating Hh
RT   signal transduction during development.";
RL   Curr. Biol. 19:1320-1326(2009).
RN   [15]
RP   INTERACTION WITH TRPS1.
RX   PubMed=19389374; DOI=10.1016/j.ydbio.2009.01.012;
RA   Wuelling M., Kaiser F.J., Buelens L.A., Braunholz D., Shivdasani R.A.,
RA   Depping R., Vortkamp A.;
RT   "Trps1, a regulator of chondrocyte proliferation and differentiation,
RT   interacts with the activator form of Gli3.";
RL   Dev. Biol. 328:40-53(2009).
RN   [16]
RP   PHOSPHORYLATION.
RX   PubMed=19878745; DOI=10.1016/j.yexcr.2009.10.018;
RA   Maloverjan A., Piirsoo M., Michelson P., Kogerman P., Osterlund T.;
RT   "Identification of a novel serine/threonine kinase ULK3 as a positive
RT   regulator of Hedgehog pathway.";
RL   Exp. Cell Res. 316:627-637(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-438; LYS-462 AND LYS-779, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 328-344 IN COMPLEX WITH SUFU, AND
RP   INTERACTION WITH SUFU.
RX   PubMed=24311597; DOI=10.1107/s0907444913028473;
RA   Cherry A.L., Finta C., Karlstrom M., Jin Q., Schwend T., Astorga-Wells J.,
RA   Zubarev R.A., Del Campo M., Criswell A.R., de Sanctis D., Jovine L.,
RA   Toftgard R.;
RT   "Structural basis of SUFU-GLI interaction in human Hedgehog signalling
RT   regulation.";
RL   Acta Crystallogr. D 69:2563-2579(2013).
RN   [21]
RP   VARIANT GCPS SER-707.
RX   PubMed=9302279; DOI=10.1093/hmg/6.11.1979;
RA   Wild A., Kalff-Suske M., Vortkamp A., Bornholdt D., Koenig R.,
RA   Grzeschik K.-H.;
RT   "Point mutations in human GLI3 cause Greig syndrome.";
RL   Hum. Mol. Genet. 6:1979-1984(1997).
RN   [22]
RP   VARIANT PAPA1 ARG-727, VARIANT PAPB ARG-727, INVOLVEMENT IN PAPA1,
RP   INVOLVEMENT IN PAPB, INVOLVEMENT IN PHS, AND INVOLVEMENT IN PPD4.
RX   PubMed=10441570; DOI=10.1086/302557;
RA   Radhakrishna U., Bornholdt D., Scott H.S., Patel U.C., Rossier C.,
RA   Engel H., Bottani A., Chandal D., Blouin J.-L., Solanki J.V.,
RA   Grzeschik K.-H., Antonarakis S.E.;
RT   "The phenotypic spectrum of GLI3 morphopathies includes autosomal dominant
RT   preaxial polydactyly type-IV and postaxial polydactyly type-A/B; no
RT   phenotype prediction from the position of GLI3 mutations.";
RL   Am. J. Hum. Genet. 65:645-655(1999).
RN   [23]
RP   VARIANT GCPS PRO-934.
RX   PubMed=12414818; DOI=10.1136/jmg.39.11.804;
RA   Elson E., Perveen R., Donnai D., Wall S., Black G.C.M.;
RT   "De novo GLI3 mutation in acrocallosal syndrome: broadening the phenotypic
RT   spectrum of GLI3 defects and overlap with murine models.";
RL   J. Med. Genet. 39:804-806(2002).
RN   [24]
RP   VARIANT GCPS TRP-625.
RX   PubMed=12794692; DOI=10.1002/ajmg.a.20018;
RA   Debeer P., Peeters H., Driess S., De Smet L., Freese K., Matthijs G.,
RA   Bornholdt D., Devriendt K., Grzeschik K.-H., Fryns J.-P., Kalff-Suske M.;
RT   "Variable phenotype in Greig cephalopolysyndactyly syndrome: clinical and
RT   radiological findings in 4 independent families and 3 sporadic cases with
RT   identified GLI3 mutations.";
RL   Am. J. Med. Genet. A 120:49-58(2003).
RN   [25]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-169 AND PRO-1304.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [26]
RP   INTERACTION WITH SUFU.
RX   PubMed=28965847; DOI=10.1016/j.ajhg.2017.08.017;
RA   De Mori R., Romani M., D'Arrigo S., Zaki M.S., Lorefice E., Tardivo S.,
RA   Biagini T., Stanley V., Musaev D., Fluss J., Micalizzi A., Nuovo S.,
RA   Illi B., Chiapparini L., Di Marcotullio L., Issa M.Y., Anello D.,
RA   Casella A., Ginevrino M., Leggins A.S., Roosing S., Alfonsi R., Rosati J.,
RA   Schot R., Mancini G.M.S., Bertini E., Dobyns W.B., Mazza T., Gleeson J.G.,
RA   Valente E.M.;
RT   "Hypomorphic Recessive Variants in SUFU Impair the Sonic Hedgehog Pathway
RT   and Cause Joubert Syndrome with Cranio-facial and Skeletal Defects.";
RL   Am. J. Hum. Genet. 101:552-563(2017).
RN   [27]
RP   INTERACTION WITH WDR11.
RX   PubMed=29263200; DOI=10.15252/embr.201744632;
RA   Kim Y.J., Osborn D.P., Lee J.Y., Araki M., Araki K., Mohun T.,
RA   Kaensaekoski J., Brandstack N., Kim H.T., Miralles F., Kim C.H.,
RA   Brown N.A., Kim H.G., Martinez-Barbera J.P., Ataliotis P., Raivio T.,
RA   Layman L.C., Kim S.H.;
RT   "WDR11-mediated Hedgehog signalling defects underlie a new ciliopathy
RT   related to Kallmann syndrome.";
RL   EMBO Rep. 19:269-289(2018).
CC   -!- FUNCTION: Has a dual function as a transcriptional activator and a
CC       repressor of the sonic hedgehog (Shh) pathway, and plays a role in limb
CC       development. The full-length GLI3 form (GLI3FL) after phosphorylation
CC       and nuclear translocation, acts as an activator (GLI3A) while GLI3R,
CC       its C-terminally truncated form, acts as a repressor. A proper balance
CC       between the GLI3 activator and the repressor GLI3R, rather than the
CC       repressor gradient itself or the activator/repressor ratio gradient,
CC       specifies limb digit number and identity. In concert with TRPS1, plays
CC       a role in regulating the size of the zone of distal chondrocytes, in
CC       restricting the zone of PTHLH expression in distal cells and in
CC       activating chondrocyte proliferation. Binds to the minimal GLI-
CC       consensus sequence 5'-GGGTGGTC-3'. {ECO:0000269|PubMed:10693759,
CC       ECO:0000269|PubMed:11238441, ECO:0000269|PubMed:17764085}.
CC   -!- SUBUNIT: The full-length GLI3 form (GLI3FL) interacts with SUFU and
CC       this interaction regulates the formation of either repressor or
CC       activator forms of GLI3. Its association with SUFU is regulated by Hh
CC       signaling and dissociation of the SUFU-GLI3 interaction requires the
CC       presence of the ciliary motor KIF3A (By similarity). Interacts with
CC       KIF7. The activator form of GLI3 (GLI3A) but not the repressor form
CC       (GLI3R) can interact with TRPS1. The phosphorylated form interacts with
CC       BTRC. Interacts with ZIC1. Interacts with ZIC3 (via C2H2-type domains
CC       3, 4 and 5); the interaction enhances its transcriptional activity.
CC       Interacts with WRD11; the interaction associates EMX1 with GLI3
CC       (PubMed:29263200). {ECO:0000250|UniProtKB:Q61602,
CC       ECO:0000269|PubMed:11238441, ECO:0000269|PubMed:16371461,
CC       ECO:0000269|PubMed:16705181, ECO:0000269|PubMed:17764085,
CC       ECO:0000269|PubMed:19389374, ECO:0000269|PubMed:19592253,
CC       ECO:0000269|PubMed:24311597, ECO:0000269|PubMed:28965847,
CC       ECO:0000269|PubMed:29263200}.
CC   -!- INTERACTION:
CC       P10071; Q9UMX1: SUFU; NbExp=3; IntAct=EBI-308055, EBI-740595;
CC       P10071; Q6ZWS8: Spop; Xeno; NbExp=2; IntAct=EBI-308055, EBI-7128920;
CC       P10071; P46684: Zic1; Xeno; NbExp=2; IntAct=EBI-308055, EBI-308006;
CC       P10071; Q62520: Zic2; Xeno; NbExp=2; IntAct=EBI-308055, EBI-308076;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cell projection, cilium.
CC       Note=GLI3FL is localized predominantly in the cytoplasm while GLI3R
CC       resides mainly in the nucleus. Ciliary accumulation requires the
CC       presence of KIF7 and SMO. Translocation to the nucleus is promoted by
CC       interaction with ZIC1.
CC   -!- TISSUE SPECIFICITY: Is expressed in a wide variety of normal adult
CC       tissues, including lung, colon, spleen, placenta, testis, and
CC       myometrium.
CC   -!- PTM: Phosphorylated on multiple sites by protein kinase A (PKA) and
CC       phosphorylation by PKA primes further phosphorylation by CK1 and GSK3.
CC       Phosphorylated by DYRK2 (in vitro). Phosphorylation is essential for
CC       its proteolytic processing.
CC   -!- PTM: Transcriptional repressor GLI3R, a C-terminally truncated form, is
CC       generated from the full-length GLI3 protein (GLI3FL/GLI3-190) through
CC       proteolytic processing. This process requires PKA-primed
CC       phosphorylation of GLI3, ubiquitination of GLI3 and the presence of
CC       BTRC. GLI3FL is complexed with SUFU in the cytoplasm and is maintained
CC       in a neutral state. Without the Hh signal, the SUFU-GLI3 complex is
CC       recruited to cilia, leading to the efficient processing of GLI3FL into
CC       GLI3R. GLI3R formation leads to its dissociation from SUFU, allowing it
CC       to translocate into the nucleus, and repress Hh target genes. When Hh
CC       signaling is initiated, SUFU dissociates from GLI3FL and this has two
CC       consequences. First, GLI3R production is halted. Second, free GLI3FL
CC       translocates to the nucleus, where it is phosphorylated, destabilized,
CC       and converted to a transcriptional activator (GLI3A). Phosphorylated in
CC       vitro by ULK3. {ECO:0000269|PubMed:16371461,
CC       ECO:0000269|PubMed:16705181}.
CC   -!- DISEASE: Greig cephalo-poly-syndactyly syndrome (GCPS) [MIM:175700]:
CC       Autosomal dominant disorder affecting limb and craniofacial
CC       development. It is characterized by pre- and postaxial polydactyly,
CC       syndactyly of fingers and toes, macrocephaly and hypertelorism.
CC       {ECO:0000269|PubMed:10441342, ECO:0000269|PubMed:12414818,
CC       ECO:0000269|PubMed:12794692, ECO:0000269|PubMed:9302279}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Pallister-Hall syndrome (PHS) [MIM:146510]: An autosomal
CC       dominant disorder characterized by a wide range of clinical
CC       manifestations. Clinical features include hypothalamic hamartoma,
CC       pituitary dysfunction, central or postaxial polydactyly, and
CC       syndactyly. Malformations are frequent in the viscera, e.g. anal
CC       atresia, bifid uvula, congenital heart malformations, pulmonary or
CC       renal dysplasia. {ECO:0000269|PubMed:10441570}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Polydactyly, postaxial A1 (PAPA1) [MIM:174200]: A condition
CC       characterized by the occurrence of supernumerary digits in the upper
CC       and/or lower extremities. In postaxial polydactyly type A, the extra
CC       digit is well-formed and articulates with the fifth or a sixth
CC       metacarpal/metatarsal. {ECO:0000269|PubMed:10441570}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Polydactyly, postaxial B (PAPB) [MIM:174200]: A condition
CC       characterized by an extra digit in the occurrence of supernumerary
CC       digits in the upper and/or lower extremities. In postaxial polydactyly
CC       type B the extra digit is not well formed and is frequently in the form
CC       of a skin. {ECO:0000269|PubMed:10441570}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Polydactyly, preaxial 4 (PPD4) [MIM:174700]: A form of
CC       polydactyly, a condition defined by the occurrence of supernumerary
CC       digits in the upper and/or lower extremities. Preaxial or radial
CC       polydactyly refers to the presence of extra digits on the radial side
CC       of the hand. PPD4 is an autosomal dominant form characterized by mild
CC       duplication of the thumb, syndactyly of various degrees affects fingers
CC       3 and 4, duplication of part or all of the first or second toes and
CC       variable toes syndactyly. Some patients have only foot involvement.
CC       {ECO:0000269|PubMed:10441570}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the GLI C2H2-type zinc-finger protein family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA52564.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M57609; AAA52564.1; ALT_FRAME; mRNA.
DR   EMBL; AJ250408; CAB59315.1; -; Genomic_DNA.
DR   EMBL; AC005026; AAP21869.1; -; Genomic_DNA.
DR   EMBL; AC005028; AAS01998.1; -; Genomic_DNA.
DR   EMBL; AC005158; AAS02015.1; -; Genomic_DNA.
DR   EMBL; AC073852; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236951; EAL24002.1; -; Genomic_DNA.
DR   EMBL; M20674; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC113616; AAI13617.1; -; mRNA.
DR   EMBL; BC117168; AAI17169.1; -; mRNA.
DR   CCDS; CCDS5465.1; -.
DR   PIR; A35927; A35927.
DR   RefSeq; NP_000159.3; NM_000168.5.
DR   PDB; 4BLD; X-ray; 2.80 A; E/F/G/H=328-344.
DR   PDBsum; 4BLD; -.
DR   SMR; P10071; -.
DR   BioGRID; 108999; 42.
DR   ComplexPortal; CPX-150; GLI3-SUFU complex.
DR   CORUM; P10071; -.
DR   DIP; DIP-32538N; -.
DR   ELM; P10071; -.
DR   IntAct; P10071; 17.
DR   MINT; P10071; -.
DR   STRING; 9606.ENSP00000379258; -.
DR   iPTMnet; P10071; -.
DR   PhosphoSitePlus; P10071; -.
DR   BioMuta; GLI3; -.
DR   DMDM; 269849770; -.
DR   EPD; P10071; -.
DR   jPOST; P10071; -.
DR   MassIVE; P10071; -.
DR   MaxQB; P10071; -.
DR   PaxDb; P10071; -.
DR   PeptideAtlas; P10071; -.
DR   PRIDE; P10071; -.
DR   ProteomicsDB; 52557; -.
DR   ABCD; P10071; 1 sequenced antibody.
DR   Antibodypedia; 647; 281 antibodies.
DR   Ensembl; ENST00000395925; ENSP00000379258; ENSG00000106571.
DR   Ensembl; ENST00000677605; ENSP00000503743; ENSG00000106571.
DR   Ensembl; ENST00000678429; ENSP00000502957; ENSG00000106571.
DR   GeneID; 2737; -.
DR   KEGG; hsa:2737; -.
DR   UCSC; uc011kbh.3; human.
DR   CTD; 2737; -.
DR   DisGeNET; 2737; -.
DR   GeneCards; GLI3; -.
DR   GeneReviews; GLI3; -.
DR   HGNC; HGNC:4319; GLI3.
DR   HPA; ENSG00000106571; Tissue enhanced (endometrium).
DR   MalaCards; GLI3; -.
DR   MIM; 146510; phenotype.
DR   MIM; 165240; gene.
DR   MIM; 174200; phenotype.
DR   MIM; 174700; phenotype.
DR   MIM; 175700; phenotype.
DR   neXtProt; NX_P10071; -.
DR   OpenTargets; ENSG00000106571; -.
DR   Orphanet; 36; Acrocallosal syndrome.
DR   Orphanet; 380; Greig cephalopolysyndactyly syndrome.
DR   Orphanet; 672; Pallister-Hall syndrome.
DR   Orphanet; 93338; Polysyndactyly.
DR   Orphanet; 93334; Postaxial polydactyly type A.
DR   Orphanet; 93335; Postaxial polydactyly type B.
DR   Orphanet; 93322; Tibial hemimelia.
DR   PharmGKB; PA28722; -.
DR   VEuPathDB; HostDB:ENSG00000106571.12; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000155925; -.
DR   HOGENOM; CLU_003666_3_0_1; -.
DR   InParanoid; P10071; -.
DR   OMA; PEHLMLH; -.
DR   OrthoDB; 56870at2759; -.
DR   PhylomeDB; P10071; -.
DR   TreeFam; TF350216; -.
DR   PathwayCommons; P10071; -.
DR   Reactome; R-HSA-5610785; GLI3 is processed to GLI3R by the proteasome.
DR   Reactome; R-HSA-5610787; Hedgehog 'off' state.
DR   Reactome; R-HSA-5632684; Hedgehog 'on' state.
DR   Reactome; R-HSA-5635851; GLI proteins bind promoters of Hh responsive genes to promote transcription.
DR   Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation.
DR   SignaLink; P10071; -.
DR   SIGNOR; P10071; -.
DR   BioGRID-ORCS; 2737; 4 hits in 1008 CRISPR screens.
DR   ChiTaRS; GLI3; human.
DR   GeneWiki; GLI3; -.
DR   GenomeRNAi; 2737; -.
DR   Pharos; P10071; Tbio.
DR   PRO; PR:P10071; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P10071; protein.
DR   Bgee; ENSG00000106571; Expressed in ventricular zone and 236 other tissues.
DR   ExpressionAtlas; P10071; baseline and differential.
DR   Genevisible; P10071; HS.
DR   GO; GO:0005930; C:axoneme; IEA:Ensembl.
DR   GO; GO:0097546; C:ciliary base; TAS:Reactome.
DR   GO; GO:0097542; C:ciliary tip; TAS:Reactome.
DR   GO; GO:0005929; C:cilium; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0017053; C:transcription repressor complex; IEA:Ensembl.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB.
DR   GO; GO:0036033; F:mediator complex binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0060873; P:anterior semicircular canal development; IEA:Ensembl.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0060840; P:artery development; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0061005; P:cell differentiation involved in kidney development; IEA:Ensembl.
DR   GO; GO:0048589; P:developmental growth; IEA:Ensembl.
DR   GO; GO:0048566; P:embryonic digestive tract development; TAS:BHF-UCL.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; TAS:BHF-UCL.
DR   GO; GO:0048702; P:embryonic neurocranium morphogenesis; IEA:Ensembl.
DR   GO; GO:0021798; P:forebrain dorsal/ventral pattern formation; IEA:Ensembl.
DR   GO; GO:0021861; P:forebrain radial glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0060364; P:frontal suture morphogenesis; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0007442; P:hindgut morphogenesis; IEA:Ensembl.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0060366; P:lambdoid suture morphogenesis; IEA:Ensembl.
DR   GO; GO:0120223; P:larynx morphogenesis; IEA:Ensembl.
DR   GO; GO:0022018; P:lateral ganglionic eminence cell proliferation; IEA:Ensembl.
DR   GO; GO:0060875; P:lateral semicircular canal development; IEA:Ensembl.
DR   GO; GO:0021819; P:layer formation in cerebral cortex; IEA:Ensembl.
DR   GO; GO:0035108; P:limb morphogenesis; IMP:UniProtKB.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0060594; P:mammary gland specification; IEA:Ensembl.
DR   GO; GO:0030318; P:melanocyte differentiation; IEA:Ensembl.
DR   GO; GO:0001656; P:metanephros development; IEA:Ensembl.
DR   GO; GO:0046639; P:negative regulation of alpha-beta T cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0045879; P:negative regulation of smoothened signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0045060; P:negative thymic T cell selection; ISS:BHF-UCL.
DR   GO; GO:0043585; P:nose morphogenesis; TAS:BHF-UCL.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0021631; P:optic nerve morphogenesis; IEA:Ensembl.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0030850; P:prostate gland development; IEA:Ensembl.
DR   GO; GO:0016485; P:protein processing; IEA:Ensembl.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl.
DR   GO; GO:1903010; P:regulation of bone development; IEA:Ensembl.
DR   GO; GO:1901620; P:regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0060021; P:roof of mouth development; IEA:Ensembl.
DR   GO; GO:0060367; P:sagittal suture morphogenesis; IEA:Ensembl.
DR   GO; GO:0007224; P:smoothened signaling pathway; IDA:FlyBase.
DR   GO; GO:0060831; P:smoothened signaling pathway involved in dorsal/ventral neural tube patterning; IEA:Ensembl.
DR   GO; GO:0021776; P:smoothened signaling pathway involved in spinal cord motor neuron cell fate specification; IEA:Ensembl.
DR   GO; GO:0021775; P:smoothened signaling pathway involved in ventral spinal cord interneuron specification; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; ISS:BHF-UCL.
DR   GO; GO:0070242; P:thymocyte apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0043586; P:tongue development; IEA:Ensembl.
DR   GO; GO:0071625; P:vocalization behavior; IEA:Ensembl.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   DisProt; DP01134; -.
DR   InterPro; IPR043359; GLI-like.
DR   InterPro; IPR032851; GLI3.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR45718; PTHR45718; 1.
DR   PANTHER; PTHR45718:SF5; PTHR45718:SF5; 1.
DR   Pfam; PF00096; zf-C2H2; 4.
DR   SMART; SM00355; ZnF_C2H2; 5.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 4.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Cell projection; Cilium; Cytoplasm;
KW   Disease variant; DNA-binding; Isopeptide bond; Metal-binding; Methylation;
KW   Nucleus; Phosphoprotein; Reference proteome; Repeat; Repressor;
KW   Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..1580
FT                   /note="Transcriptional activator GLI3"
FT                   /id="PRO_0000047202"
FT   CHAIN           1..?
FT                   /note="Transcriptional repressor GLI3R"
FT                   /id="PRO_0000406137"
FT   ZN_FING         480..505
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         513..540
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         546..570
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         576..601
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         607..632
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   COMPBIAS        1492..1512
FT                   /note="Asp/Glu-rich (acidic)"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         175
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61602"
FT   MOD_RES         664
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         849
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:10693759"
FT   MOD_RES         865
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:10693759"
FT   MOD_RES         877
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:10693759"
FT   MOD_RES         907
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:10693759"
FT   MOD_RES         980
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:10693759"
FT   MOD_RES         1006
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:10693759"
FT   CROSSLNK        438
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        462
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        773
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   CROSSLNK        779
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        779
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   CROSSLNK        784
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   CROSSLNK        800
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   VARIANT         169
FT                   /note="P -> L (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1419861206)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035560"
FT   VARIANT         183
FT                   /note="T -> A (in dbSNP:rs846266)"
FT                   /evidence="ECO:0000269|PubMed:10441342,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:2118997"
FT                   /id="VAR_028276"
FT   VARIANT         440
FT                   /note="D -> E"
FT                   /evidence="ECO:0000269|PubMed:10441342"
FT                   /id="VAR_010052"
FT   VARIANT         515
FT                   /note="C -> G (in GCPS)"
FT                   /evidence="ECO:0000269|PubMed:10441342"
FT                   /id="VAR_010053"
FT   VARIANT         520
FT                   /note="C -> Y (in GCPS)"
FT                   /evidence="ECO:0000269|PubMed:10441342"
FT                   /id="VAR_010054"
FT   VARIANT         625
FT                   /note="R -> W (in GCPS; dbSNP:rs121917712)"
FT                   /evidence="ECO:0000269|PubMed:12794692"
FT                   /id="VAR_021481"
FT   VARIANT         707
FT                   /note="P -> S (in GCPS; dbSNP:rs121917716)"
FT                   /evidence="ECO:0000269|PubMed:9302279"
FT                   /id="VAR_010055"
FT   VARIANT         727
FT                   /note="G -> R (in PAPA1 and PAPB; dbSNP:rs121917710)"
FT                   /evidence="ECO:0000269|PubMed:10441570"
FT                   /id="VAR_009876"
FT   VARIANT         808
FT                   /note="I -> M (in dbSNP:rs62622373)"
FT                   /evidence="ECO:0000269|PubMed:10441342"
FT                   /id="VAR_010056"
FT   VARIANT         934
FT                   /note="A -> P (in GCPS; the patient was originally
FT                   classifed as being affected by acrocallosal syndrome due to
FT                   the absence of corpus callosum; dbSNP:rs28933372)"
FT                   /evidence="ECO:0000269|PubMed:12414818"
FT                   /id="VAR_021482"
FT   VARIANT         998
FT                   /note="P -> L (in dbSNP:rs929387)"
FT                   /evidence="ECO:0000269|PubMed:10441342,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:2118997"
FT                   /id="VAR_028278"
FT   VARIANT         1304
FT                   /note="S -> P (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1277170270)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035561"
FT   VARIANT         1336
FT                   /note="G -> E (in dbSNP:rs35280470)"
FT                   /id="VAR_034865"
FT   VARIANT         1537
FT                   /note="R -> C (in dbSNP:rs35364414)"
FT                   /evidence="ECO:0000269|PubMed:10441342"
FT                   /id="VAR_010057"
FT   MUTAGEN         773
FT                   /note="K->R: Loss of proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   MUTAGEN         779
FT                   /note="K->R: Loss of proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   MUTAGEN         784
FT                   /note="K->R: Loss of proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   MUTAGEN         800
FT                   /note="K->R: Loss of proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   MUTAGEN         849
FT                   /note="S->A: Loss of phosphorylation and proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:10693759,
FT                   ECO:0000269|PubMed:16705181"
FT   MUTAGEN         855
FT                   /note="S->A: Loss of proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   MUTAGEN         856
FT                   /note="S->A: Loss of proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   MUTAGEN         861
FT                   /note="S->A: Loss of proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   MUTAGEN         864
FT                   /note="S->A: Loss of proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   MUTAGEN         865
FT                   /note="S->A: Loss of phosphorylation and proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:10693759"
FT   MUTAGEN         873
FT                   /note="S->A: Loss of proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   MUTAGEN         877
FT                   /note="S->A: Loss of phosphorylation and proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:10693759,
FT                   ECO:0000269|PubMed:16705181"
FT   MUTAGEN         903
FT                   /note="S->A: Loss of proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:16705181"
FT   MUTAGEN         907
FT                   /note="S->A: Loss of phosphorylation and proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:10693759,
FT                   ECO:0000269|PubMed:16705181"
FT   MUTAGEN         980
FT                   /note="S->A: Loss of phosphorylation and proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:10693759"
FT   MUTAGEN         1006
FT                   /note="S->A: Loss of phosphorylation and proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:10693759"
FT   STRAND          334..337
FT                   /evidence="ECO:0007744|PDB:4BLD"
SQ   SEQUENCE   1580 AA;  169863 MW;  423B7495FCE3C37C CRC64;
     MEAQSHSSTT TEKKKVENSI VKCSTRTDVS EKAVASSTTS NEDESPGQTY HRERRNAITM
     QPQNVQGLSK VSEEPSTSSD ERASLIKKEI HGSLPHVAEP SVPYRGTVFA MDPRNGYMEP
     HYHPPHLFPA FHPPVPIDAR HHEGRYHYDP SPIPPLHMTS ALSSSPTYPD LPFIRISPHR
     NPTAASESPF SPPHPYINPY MDYIRSLHSS PSLSMISATR GLSPTDAPHA GVSPAEYYHQ
     MALLTGQRSP YADIIPSAAT AGTGAIHMEY LHAMDSTRFS SPRLSARPSR KRTLSISPLS
     DHSFDLQTMI RTSPNSLVTI LNNSRSSSSA SGSYGHLSAS AISPALSFTY SSAPVSLHMH
     QQILSRQQSL GSAFGHSPPL IHPAPTFPTQ RPIPGIPTVL NPVQVSSGPS ESSQNKPTSE
     SAVSSTGDPM HNKRSKIKPD EDLPSPGARG QQEQPEGTTL VKEEGDKDES KQEPEVIYET
     NCHWEGCARE FDTQEQLVHH INNDHIHGEK KEFVCRWLDC SREQKPFKAQ YMLVVHMRRH
     TGEKPHKCTF EGCTKAYSRL ENLKTHLRSH TGEKPYVCEH EGCNKAFSNA SDRAKHQNRT
     HSNEKPYVCK IPGCTKRYTD PSSLRKHVKT VHGPEAHVTK KQRGDIHPRP PPPRDSGSHS
     QSRSPGRPTQ GALGEQQDLS NTTSKREECL QVKTVKAEKP MTSQPSPGGQ SSCSSQQSPI
     SNYSNSGLEL PLTDGGSIGD LSAIDETPIM DSTISTATTA LALQARRNPA GTKWMEHVKL
     ERLKQVNGMF PRLNPILPPK APAVSPLIGN GTQSNNTCSL GGPMTLLPGR SDLSGVDVTM
     LNMLNRRDSS ASTISSAYLS SRRSSGISPC FSSRRSSEAS QAEGRPQNVS VADSYDPIST
     DASRRSSEAS QSDGLPSLLS LTPAQQYRLK AKYAAATGGP PPTPLPNMER MSLKTRLALL
     GDALEPGVAL PPVHAPRRCS DGGAHGYGRR HLQPHDAPGH GVRRASDPVR TGSEGLALPR
     VPRFSSLSSC NPPAMATSAE KRSLVLQNYT RPEGGQSRNF HSSPCPPSIT ENVTLESLTM
     DADANLNDED FLPDDVVQYL NSQNQAGYEQ HFPSALPDDS KVPHGPGDFD APGLPDSHAG
     QQFHALEQPC PEGSKTDLPI QWNEVSSGSA DLSSSKLKCG PRPAVPQTRA FGFCNGMVVH
     PQNPLRSGPA GGYQTLGENS NPYGGPEHLM LHNSPGSGTS GNAFHEQPCK APQYGNCLNR
     QPVAPGALDG ACGAGIQASK LKSTPMQGSG GQLNFGLPVA PNESAGSMVN GMQNQDPVGQ
     GYLAHQLLGD SMQHPGAGRP GQQMLGQISA TSHINIYQGP ESCLPGAHGM GSQPSSLAVV
     RGYQPCASFG GSRRQAMPRD SLALQSGQLS DTSQTCRVNG IKMEMKGQPH PLCSNLQNYS
     GQFYDQTVGF SQQDTKAGSF SISDASCLLQ GTSAKNSELL SPGANQVTST VDSLDSHDLE
     GVQIDFDAII DDGDHSSLMS GALSPSIIQN LSHSSSRLTT PRASLPFPAL SMSTTNMAIG
     DMSSLLTSLA EESKFLAVMQ
//
